Doxorubicin plus Ifosfamide as Salvage Treatment for Patients with Advanced Breast Cancer Refractory to Epirubicin plus Cyclophosphamide

By Polyzos A.  

Clinical Drug Investigation, Vol. 19, Iss. 5, 2000-05 ,pp. : 349-355

Adis International

Access to resources Recommend Favorite

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer

By Galsky Matthew D.   Pal Sumanta K.   Chowdhury Simon   Harshman Lauren C.   Crabb Simon J.   Wong Yu-Ning   Yu Evan Y.   Powles Thomas   Moshier Erin L.   Ladoire Sylvain   Hussain Syed A.   Agarwal Neeraj   Vaishampayan Ulka N.   Recine Federica   Berthold Dominik   Necchi Andrea   Theodore Christine   Milowsky Matthew I.   Bellmunt Joaquim   Rosenberg Jonathan E.   Galsky Matthew D.  

Cancer, Vol. 121, Iss. 15, 2015-08 ,pp. : 2586-2593

Blackwell Publishing

Access to resources Recommend Favorite

Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3923-3931

Blackwell Publishing

Access to resources Recommend Favorite

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors

By Medioni Jacques   Huchon Cyrille   >  

Drugs in R&D, Vol. 11, Iss. 2, 2011-06 ,pp. : 147-157

Adis International

Access to resources Recommend Favorite

Adjuvant regimen with docetaxel best bet in operable breast cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 480, 2005-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite